Dry powder nebulizer developer Nob Hill Therapeutics announced the appointment of Noel Greenberger as its new CEO, replacing interim CEO Yun Li as of September 1, and said that it has received a Department of Health and Human Services (HHS) Small Business Innovation Research (SBIR) Phase 2 grant of up to $1.73 million for development of a dry powder antifungal delivered by the company’s DryNeb device.
Greenberger, who was formerly Executive Directory of Respiratory at Sandoz, was most recently Chief Commercial Officer of Vertice Pharma. He commented, “I’m thrilled to join Nob Hill. Nob Hill is poised to deliver both meaningful therapies to patients and value to its investors. The Nob Hill team has done tremendous work to date, and I look forward to working with them and building on the momentum gained during the last several months.”
Nob Hill Executive Chairman Paul J. Atkins said, “This is an exciting time for Nob Hill. Over the past year we have established a strong foundation for the company and continued to develop our platform delivery device (DryNeb). The SBIR grant award further validates the potential benefit of this delivery technology to develop therapies to treat severe lung infections.”
Li added, “This grant is built on our successful Phase 1 grant work conducted a year ago, which delivered encouraging animal efficacy study results. The timing is perfect as we are making significant progress on the device which is now in laboratory testing.”
Read the Nob Hill Therapeutics press release.
